Eli Lilly And Co Drug Patent Portfolio
Eli Lilly And Co owns 11 orange book drugs protected by 37 US patents with Prozac having the least patent protection, holding only 1 patent. And Axiron with maximum patent protection, holding 11 patents. Given below is the list of Eli Lilly And Co's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12071423 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | 06 Jul, 2040 | Active |
| US11357820 | GIP/GLP1 agonist compositions | 14 Jun, 2039 | Active |
| US11918623 | GIP/GLP1 agonist compositions | 14 Jun, 2039 | Active |
| US10584124 | Crystalline forms | 10 Oct, 2038 | Active |
| US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile | 10 Oct, 2038 | Active |
| US12138250 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | 10 Oct, 2038 | Active |
| US11053214 | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists | 05 Dec, 2037 | Active |
| US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
| US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
| US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
| US9474780 | GIP and GLP-1 co-agonist compounds | 05 Jan, 2036 | Active |
| US11045474 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections | 30 Nov, 2032 | Active |
| US9089574 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | 30 Nov, 2032 | Active |
| US8158616 | Azetidine and cyclobutane derivatives as JAK inhibitors | 31 May, 2032 | Active |
| US11806555 | Methods for treating hair loss disorders | 02 Nov, 2031 | Active |
| US9737469 | Methods for treating hair loss disorders | 02 Nov, 2031 | Active |
| US7855211 | Protein kinase inhibitors | 28 Sep, 2031 | Active |
| US9402957 | Automatic injection device with delay mechanism including dual functioning biasing member | 29 Jun, 2031 | Active |
| US8734394 | Automatic injection device with delay mechanism including dual functioning biasing member | 24 Feb, 2031 | Active |
| US8420629 | Azetidine and cyclobutane derivatives as JAK inhibitors | 10 Mar, 2029 | Active |
| US7423050 | Pyridinoylpiperidines as 5-HT1F agonists | 17 Feb, 2028 | Active |
| US8435944 | Method and composition for transdermal drug delivery | 27 Sep, 2027 | Active |
| US8419307 | Spreading implement | 26 Feb, 2027 | Active |
| US8807861 | Spreading implement | 26 Feb, 2027 | Active |
| US9289586 | Spreading implement | 26 Feb, 2027 | Active |
| US8993520 | Method and composition for transdermal drug delivery | 02 Jun, 2026 | Active |
| US9180194 | Method and composition for transdermal drug delivery | 02 Jun, 2026 | Active |
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage | 09 Aug, 2024 | Expired |
| US8784878 | Transdermal delivery rate control using amorphous pharmaceutical compositions | 13 Jul, 2023 | Expired |
| US8748459 | Pyridinoylpiperidines as 5-HT1F agonists | 27 Mar, 2023 | Expired |
| US6034054 | Stable insulin formulations | 11 Jun, 2018 | Expired |
| US6551992 | Stable insulin formulations | 11 Jun, 2018 | Expired |
| US6960577 | Combination therapy for treatment of refractory depression | 01 Nov, 2017 | Expired |
| US6299900 | Dermal penetration enhancers and drug delivery systems involving same | 19 Feb, 2017 | Expired |
| US6818226 | Dermal penetration enhancers and drug delivery systems involving same | 19 Feb, 2017 | Expired |
| US6923983 | Transdermal delivery of hormones | 19 Feb, 2017 | Expired |
| US8071075 | Dermal penetration enhancers and drug delivery systems involving the same | 19 Feb, 2017 | Expired |
Latest Legal Activities on Eli Lilly And Co's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eli Lilly And Co.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9474780 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9474780 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11918623 |
|
Email Notification
Critical
| 05 Mar, 2024 | US11918623 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11918623 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918623 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11918623 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918623 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11918623 |
|
Email Notification
Critical
| 05 Mar, 2024 | US11918623 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9474780 |
Eli Lilly And Co Drug Patents' Oppositions Filed in EPO
Eli Lilly And Co drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 26, 2017, by Müller Fottner Steinecke Rechtsanwalts- Und Patentanwaltspartnerschaft Mbb. This opposition was filed on patent number EP03729716A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11838771A | Apr, 2020 | Concert Pharmaceuticals, Inc. | Granted and Under Opposition |
| EP06741180A | Aug, 2017 | Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB | Revoked |
| EP03729716A | Apr, 2017 | Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB | Revoked |
Eli Lilly And Co's Family Patents
Eli Lilly And Co Drug List
Given below is the complete list of Eli Lilly And Co's drugs and the patents protecting them.
1. Axiron
Axiron is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8435944 | Method and composition for transdermal drug delivery |
27 Sep, 2027
(2 years from now)
| Active |
| US8419307 | Spreading implement |
26 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8807861 | Spreading implement |
26 Feb, 2027
(1 year, 9 months from now)
| Active |
| US9289586 | Spreading implement |
26 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8993520 | Method and composition for transdermal drug delivery |
02 Jun, 2026
(1 year, 6 days from now)
| Active |
| US9180194 | Method and composition for transdermal drug delivery |
02 Jun, 2026
(1 year, 6 days from now)
| Active |
| US8784878 | Transdermal delivery rate control using amorphous pharmaceutical compositions |
13 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US6299900 | Dermal penetration enhancers and drug delivery systems involving same |
19 Feb, 2017
(8 years ago)
| Expired |
| US6818226 | Dermal penetration enhancers and drug delivery systems involving same |
19 Feb, 2017
(8 years ago)
| Expired |
| US6923983 | Transdermal delivery of hormones |
19 Feb, 2017
(8 years ago)
| Expired |
| US8071075 | Dermal penetration enhancers and drug delivery systems involving the same |
19 Feb, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axiron's drug page
2. Humalog Kwikpen
Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
| US6034054 | Stable insulin formulations |
11 Jun, 2018
(6 years ago)
| Expired |
| US6551992 | Stable insulin formulations |
11 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page
3. Mounjaro
Mounjaro is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11357820 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US9474780 | GIP and GLP-1 co-agonist compounds |
05 Jan, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro's drug page
4. Mounjaro (autoinjector)
Mounjaro (autoinjector) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11357820 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US9474780 | GIP and GLP-1 co-agonist compounds |
05 Jan, 2036
(10 years from now)
| Active |
| US9402957 | Automatic injection device with delay mechanism including dual functioning biasing member |
29 Jun, 2031
(6 years from now)
| Active |
| US8734394 | Automatic injection device with delay mechanism including dual functioning biasing member |
24 Feb, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro (autoinjector)'s drug page
5. Olumiant
Olumiant is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11045474 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
30 Nov, 2032
(7 years from now)
| Active |
| US9089574 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
30 Nov, 2032
(7 years from now)
| Active |
| US8158616 | Azetidine and cyclobutane derivatives as JAK inhibitors |
31 May, 2032
(7 years from now)
| Active |
| US11806555 | Methods for treating hair loss disorders |
02 Nov, 2031
(6 years from now)
| Active |
| US9737469 | Methods for treating hair loss disorders |
02 Nov, 2031
(6 years from now)
| Active |
| US8420629 | Azetidine and cyclobutane derivatives as JAK inhibitors |
10 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olumiant's drug page
Explore Our Curated Drug Screens
6. Prozac
Prozac is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960577 | Combination therapy for treatment of refractory depression |
01 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac's drug page
7. Retevmo
Retevmo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10584124 | Crystalline forms |
10 Oct, 2038
(13 years from now)
| Active |
| US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
10 Oct, 2038
(13 years from now)
| Active |
| US12138250 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
10 Oct, 2038
(13 years from now)
| Active |
| US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
| US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
| US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retevmo's drug page
8. Reyvow
Reyvow is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12071423 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate |
06 Jul, 2040
(15 years from now)
| Active |
| US11053214 | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
05 Dec, 2037
(12 years from now)
| Active |
| US7423050 | Pyridinoylpiperidines as 5-HT1F agonists |
17 Feb, 2028
(2 years from now)
| Active |
| US8748459 | Pyridinoylpiperidines as 5-HT1F agonists |
27 Mar, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyvow's drug page
9. Verzenio
Verzenio is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7855211 | Protein kinase inhibitors |
28 Sep, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verzenio's drug page
10. Zepbound
Zepbound is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11357820 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US11918623 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US9474780 | GIP and GLP-1 co-agonist compounds |
05 Jan, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound's drug page
11. Zepbound (autoinjector)
Zepbound (autoinjector) is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11357820 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US11918623 | GIP/GLP1 agonist compositions |
14 Jun, 2039
(14 years from now)
| Active |
| US9474780 | GIP and GLP-1 co-agonist compounds |
05 Jan, 2036
(10 years from now)
| Active |
| US9402957 | Automatic injection device with delay mechanism including dual functioning biasing member |
29 Jun, 2031
(6 years from now)
| Active |
| US8734394 | Automatic injection device with delay mechanism including dual functioning biasing member |
24 Feb, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound (autoinjector)'s drug page